Neisseria meningitidis compositions and methods thereof

US9561269B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9561269-B2
Application numberUS-201514604620-A
CountryUS
Kind codeB2
Filing dateJan 23, 2015
Priority dateMar 9, 2012
Publication dateFeb 7, 2017
Grant dateFeb 7, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.

First claim

Opening claim text (preview).

What is claimed is: 1. An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 76. 2. The isolated polypeptide according to claim 1 , wherein the polypeptide is lipidated. 3. The isolated polypeptide according to claim 1 , wherein the polypeptide is non-lipidated. 4. The isolated polypeptide according to claim 1 , wherein the polypeptide is immunogenic. 5. An isolated polypeptide comprising the sequence set forth in SEQ ID NO: 76, wherein the cysteine at position 1 is deleted. 6. The isolated polypeptide according to claim 5 , wherein the polypeptide does not exhibit a mass shift of about +70 Da compared to the corresponding non-lipidated polypeptide as measured by mass spectrometry. 7. An isolated polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 76. 8. The isolated polypeptide according to claim 7 , wherein the polypeptide is lipidated. 9. The isolated polypeptide according to claim 7 , wherein the polypeptide is non-lipidated. 10. The isolated polypeptide according to claim 7 , wherein the polypeptide is immunogenic. 11. An immunogenic composition comprising the polypeptide as in any one of claims 1 - 10 . 12. The composition of claim 11 , further comprising an adjuvant.

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9561269B2 cover?
In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningoc…
Who is the assignee on this patent?
Pfizer
What technology area does this patent fall under?
Primary CPC classification C07K14/22. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).